GlassScriptPhysician profile
Concettina Peloro
NPI 1174588321
$566.88
in general payments reported to CMS, 2019-2025
12 companies · $69.65 in 2025
The $69.65 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.67 · 2020: $41.88 · 2022: $164 · 2023: $118 · 2024: $105 · 2025: $69.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $164.58 | 2020-2025 | Tremfya |
| Lilly USA, LLC | $89.09 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $61.20 | 2022-2024 | |
| Organogenesis INC. | $48.46 | 2022 | |
| Pfizer INC. | $42.73 | 2019-2022 | |
| Incyte Corporation | $31.17 | 2024 | Opzelura |
| Leo Pharma INC. | $30.22 | 2019-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $30.06 | 2020-2023 | Ilumya |
| Genentech USA, INC. | $26.13 | 2019 | |
| Amgen INC. | $17.15 | 2024 | Otezla |
| Ucb, INC. | $14.12 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Concettina Peloro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.